A rhizoma chuanxiong extract for treating diabetic nephropathy and preparation method thereof

By using ethanol solution extraction and macroporous resin column separation technology, the target components were screened out and efficient Chuanxiong extract was prepared, which solved the problem that the existing treatment methods for diabetic nephropathy could not effectively block the pathological progress, significantly improving the efficacy and The drug quality was stabilized and the pathological status of diabetic nephropathy mice was improved.

CN116421639BActive Publication Date: 2024-11-12SHANDONG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310293795.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-21
Publication Date
2024-11-12
Estimated Expiration
2043-03-21

AI Technical Summary

Technical Problem

The existing treatment of diabetic nephropathy cannot effectively block pathological progression, resulting in patients relying on dialysis and kidney transplantation, which seriously affects the quality of life.

Method used

Chuanxiong was extracted with 65%-95% ethanol solution and soaked and refluxed. Combined with macroporous adsorption resin column separation and purification, the target components were screened through QR induction activity experiment and NO generation inhibition experiment to prepare efficient Chuanxiong extract.

Benefits of technology

It significantly improves the efficacy of the drug, reduces the dosage of the drug, ensures the stable quality of the drug, can reduce glomerular hypertrophy, renal fibrosis and inflammation in diabetic nephropathy mice, reduces the level of oxidative stress, and has antioxidant and neuroprotective effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116421639B_ABST
    Figure CN116421639B_ABST
Patent Text Reader

Abstract

The invention discloses a chuanxiong extract for treating diabetic nephropathy and a preparation method thereof, comprising the following steps: using 65%-95% ethanol solution as an extraction solvent, soaking chuanxiong for 3-5h at 20-30°C, and then extracting at 50-100°C for 2-4h to obtain an extract; refining, concentrating and drying the extract to obtain an ethanol extract of chuanxiong; using a macroporous adsorption resin column to separate and purify the ethanol extract of chuanxiong, and collecting each part of the eluate; concentrating and drying each part of the eluate to obtain each part of the extract; using QR induction activity experiment and NO generation inhibition experiment to screen the obtained extracts of each part to obtain a target component. By adopting a specific extraction, refining and effective component separation and purification method, the content of the effective component is relatively increased, while keeping the content ratio between the effective components stable, thereby significantly improving the efficacy, reducing the amount of drug taken and ensuring the stable quality of the drug.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of preparation of chuanxiong extract, and particularly relates to a chuanxiong extract for treating diabetic nephropathy and a preparation method thereof. Background Art

[0002] The statements herein merely provide background information related to the present invention and do not necessarily constitute prior art.

[0003] Diabetic nephropathy (DN) is a complication induced by diabetic microangiopathy. Its clinical features include degenerative changes such as varying degrees of proteinuria, glomerular sclerosis and hypertrophy, and renal fibrosis, which in turn increase the risk of chronic kidney disease (CKD) and end-stage renal disease (ESRD), as well as the risk of premature death in patients, bringing a huge socioeconomic burden. Clinical treatment methods mainly control blood sugar, blood pressure, and blood lipids. First-line medications are mostly hypoglycemic and antihypertensive drugs to delay DN lesions, but they cannot effectively block the pathological progression of DN. When DN develops into end-stage renal disease, it can only be treated with dialysis and kidney transplantation, which seriously affects the quality of life of patients. Summary of the invention

[0004] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a Chuanxiong extract for treating diabetic nephropathy and a preparation method thereof. By adopting a specific extraction, refining and effective component separation and purification method, the content of the effective component is relatively increased, while the content ratio between the effective components is kept stable, thereby significantly improving the efficacy, reducing the dosage of the drug and ensuring the stability of the drug quality.

[0005] In order to achieve the above object, the present invention is implemented through the following technical solutions:

[0006] In a first aspect, the present invention provides a method for preparing a Ligusticum chuanxiong extract for treating diabetic nephropathy, comprising the following steps:

[0007] Using 65%-95% ethanol solution as extraction solvent, soaking Chuanxiong at 20-30°C for 3-5h, and then reflux extraction at 50-100°C for 2-4h to obtain an extract;

[0008] The extract is refined, concentrated and dried to obtain the ethanol extract of Chuanxiong;

[0009] Using a macroporous adsorption resin column to separate and purify the ethanol extract of Chuanxiong, and collecting the eluents of each part;

[0010] The eluates of each part are concentrated and dried to obtain extracts of each part;

[0011] The QR induction activity experiment and NO generation inhibition experiment were used to screen the extracts from various parts to obtain the target components.

[0012] 65%-95% ethanol is a volume percentage. Too low ethanol concentration will result in more water-soluble components such as sugars, while small polar compounds such as phthalides will not be completely extracted.

[0013] Soaking with extraction solvent before heating and refluxing is beneficial to the precipitation of various effective ingredients and shortens the decoction time.

[0014] Extraction temperature is an important part of extraction. Too low temperature may reduce the dissolution and diffusion rate of active substances, which is not conducive to leaching; but too high temperature may also cause some effective ingredients to become ineffective. At the same time, during high-temperature extraction, the leaching amount of ineffective ingredients and auxiliary ingredients will also increase, which will not only increase the impurities in the extract, but also make subsequent refining difficult.

[0015] Macroporous resin is selected because it is cheap and reusable, and the eluent is water-ethanol, which is cheap, non-toxic, and highly safe. Compared with other separation methods, it is more suitable for large-scale industrial production.

[0016] In some embodiments, the mass of the extraction solvent is 8-12 times the mass of Chuanxiong. Too little solvent during extraction will lead to incomplete extraction of the active substances and reduce the yield; too much solvent will lead to a long subsequent rotary evaporation drying time, and the extraction process will be time-consuming, labor-intensive and wasteful.

[0017] In some embodiments, the extraction temperature is 70-90°C.

[0018] In some embodiments, the refining method is an activated carbon adsorption clarification method or a reduced pressure filtration method.

[0019] In some embodiments, the macroporous adsorption resin column is D101, D201, D301, HPD-100, HPD-400, HPD-BJQH, or AB-8.

[0020] Preferably, the macroporous adsorption resin column is HPD-100, HPD-400, or D101.

[0021] Preferably, when a macroporous adsorption resin column is used for separation, the eluent is 60%-70% ethanol by volume, the elution volume is 3-5 BV, and the elution flow rate is 1.5-2.5 BV / h;

[0022] Further preferably, the eluent is 67%-70% ethanol by volume;

[0023] More preferably, the eluent is 67.5% ethanol by volume.

[0024] In some embodiments, the drying is vacuum drying or freeze drying.

[0025] In a second aspect, the present invention provides a Chuanxiong extract for treating diabetic nephropathy, which is prepared by the preparation method, and comprises 1"-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxyphthalide, wherein the structural formulas of 1"-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxyphthalide are respectively as follows:

[0026]

[0027] Preferably, the active ingredients of the Chuanxiong extract include ligusticumolide C, ligusticum lactone A, 6S,7S-3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrobenzamide, ligusticum lactone L3, ligusticum lactone M, thioligusticum lactone A, ligusticum lactone E, ligusticum lactone L2, ligusticum lactone C, (-)-all0aromadendrane-4β,10α,13,15-tetrol, ligusticum lactone A, Z-ligusticum lactone, oriental angelica lactone B and angelica lactone A.

[0028] In a third aspect, the present invention provides a diabetic nephropathy drug, the active ingredient of which includes the Chuanxiong extract.

[0029] The dosage form is one of tablets, capsules, granules, and oral liquid.

[0030] The beneficial effects achieved by one or more embodiments of the present invention are as follows:

[0031] In order to discover the active components from Chuanxiong, macroporous resin was used to separate and prepare Chuanxiong, and the in vitro anti-inflammatory and antioxidant capacity of each component was tested by QR induced activity experiment and NO generation inhibition experiment. Finally, the most active effective component was selected, and the components of the component were identified by UPLC-MS / MS and HPLC. It was identified that it contained phthalide, phenolic acid and other compounds, and two new compounds were also identified. Subsequently, the in vivo effectiveness of this component on diabetic nephropathy was explored, and drugs or health products with the ability to treat or prevent diabetic nephropathy were developed.

[0032] The extract prepared can reduce glomerular hypertrophy, kidney hypertrophy and inflammatory cell aggregation in diabetic nephropathy mice; it can reduce renal fibrosis and matrix expansion in diabetic nephropathy mice. In diabetes-induced neuropathy, the extract can reduce the level of oxidative stress in the brain of diabetic nephropathy mice, increase the activity of SOD and CAT in the brain tissue of DN mice, and reduce the production of lipid peroxide MDA, thus playing a neuroprotective role through this antioxidant effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0034] Figure 1 This is a process flow chart for optimizing the extraction conditions of Chuanxiong of the present invention;

[0035] Figure 2 The NO generation inhibition activity (a) and QR induction activity (b) of each component in Example 2 of the present invention;

[0036] Figure 3 It is the liquid-mass analysis spectrum of the effective components in Example 2 of the present invention;

[0037] Figure 4 This is a curve comparison of the effects of the effective components in Example 4 of the present invention on the body weight (a) and blood sugar (b) of DN mice. Among them, the blank group is a normal wild C57BL / 6 control mouse, the model is a DN model mouse, the positive drug group is a DN mouse gavage captopril group, the effective component low-dose group is a DN mouse gavage 10 mg / kg group, the effective component high-dose group is a mouse gavage 20 mg / kg group, and the Chuanxiong extract is a DN mouse gavage Chuanxiong ethanol extract 20 mg / kg group.

[0038] Figure 5 This is the HE staining of the kidney of DN mice in Example 6 of the present invention. It can be seen that the effective component can reduce glomerular hypertrophy and renal hypertrophy in DN mice. The blank group is a normal wild C57BL / 6 control mouse, the model is a DN model mouse, the positive drug group is a DN mouse gavage captopril group, the effective component low-dose group is a DN mouse gavage 10 mg / kg group, the effective component high-dose group is a mouse gavage 20 mg / kg group, and the Chuanxiong extract is a DN mouse gavage Chuanxiong ethanol extract 20 mg / kg group.

[0039] Figure 6This is the PAS staining diagram of the kidney of DN mice in Example 6 of the present invention. It can be seen that the effective component can reduce the matrix expansion of DN mice. The blank group is a normal wild C57BL / 6 control mouse, the model is a DN model mouse, the positive drug group is a DN mouse gavage captopril group, the effective component low-dose group is a DN mouse gavage 10 mg / kg group, the effective component high-dose group is a mouse gavage 20 mg / kg group, and the Chuanxiong extract is a DN mouse gavage Chuanxiong ethanol extract 20 mg / kg group.

[0040] Figure 7 This is a comparison chart of the effects of the effective components in Example 7 of the present invention on the fibrosis indicators TGF-β1, α-SMA, and the classic antioxidant pathway Nrf2 and its downstream proteins NQO1 and GCLM in the renal tissue of DN mice. Among them, the blank group is a normal wild C57BL / 6 control mouse, the model is a DN model mouse, the positive drug group is a DN mouse gavage captopril group, the effective component low-dose group is a DN mouse gavage 10 mg / kg group, the effective component high-dose group is a mouse gavage 20 mg / kg group, and the Chuanxiong extract is a DN mouse gavage Chuanxiong ethanol extract 20 mg / kg group.

[0041] Figure 8 The effective component in Example 8 of the present invention inhibits the activation of the NF-κB signaling pathway induced by LPS at the cellular level. The blank group is normal RAW264.7 (mouse mononuclear macrophages), the positive control drug is Didox, and 3, 6, 12, and 24 are the concentrations of the effective component (μg / mL).

[0042] Fig. 9 This is a characterization diagram of the new compound 1”-ethoxy-wallichilide, where a is the mass spectrum; b is 1 H (600Hz) spectrum; c is 13 C (150Hz) spectrum;

[0043] Fig.10 is the characterization diagram of the new compound 3-butylene-6-hydroxy-7-ethoxyphthalide, where a is the mass spectrum; b is 1 H (600Hz) spectrum; c is 13 C (150Hz) spectrum. DETAILED DESCRIPTION

[0044] It should be noted that the following detailed descriptions are illustrative and intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0045] Example 1 Preparation of active ingredients

[0046] 10 kg of Chuanxiong medicinal materials (the quality of raw materials meets the requirements of the Pharmacopoeia of the People's Republic of China 2020 edition (Part 1)) were crushed and soaked at room temperature for 4 hours. The amount of extraction solvent was 10 times the weight of the medicinal materials. A single factor experiment was used to investigate the effects of extraction ethanol concentration, extraction temperature, extraction time, and reflux times. The specific parameters investigated were as follows: Figure 1 By examining the above variables, the best process was finally selected: the amount of solvent used each time was 10 times the weight of the medicinal material, the extraction time was 3 hours each time, refluxed twice, the ethanol concentration was 75%, and the extraction temperature was 85°C; the extracts were combined, and the extracts were refined by activated carbon adsorption clarification and vacuum filtration to obtain refined liquid, which was concentrated and dried to obtain Chuanxiong ethanol extract.

[0047] Considering that macroporous resins are inexpensive and reusable and suitable for large-scale industrial production, macroporous resins were selected for coarse separation. Seven types of macroporous resins were selected for separation, namely D101, D201, D301, HPD-100, HPD-400, HPD-BJQH, and AB-8. The eluent was ethanol-water (0-100%). The obtained fractions were used for QR activity induction experiments and NO generation inhibition experiments to preliminarily evaluate the enrichment degree of different types of macroporous resins for anti-inflammatory and antioxidant components. Combined with the yield of each macroporous resin, it was found that HPD-100, HPD-400, D101 and other types of macroporous resins were the best, and then the macroporous resin column process was investigated.

[0048] First, the optimal elution concentration was determined: the eluent was ethanol-water, and the gradient range was reduced in sequence according to the activity tracking to screen out the optimal elution concentration. First, the volume percentages of ethanol solutions were 0%, 30%, 50%, 70%, 85%, and 100%, respectively. According to the activity screening results, the active sites were locked in the part with an ethanol content of 50%-70%, and the elution ratio range was further narrowed to set the following elution ratios: 50%, 52.5%, 55%, 57.5%, 60%, 62.5%, 65%, 67.5%, and 70%. These nine components were subjected to QR activity screening and NO generation inhibition assays, and it was found that the part with the best activity was the component eluted at an ethanol concentration of 67.5%. Therefore, the optimal elution concentration was determined to be an ethanol-water solution with a volume percentage of 67.5%, an elution volume of 4BV, an elution flow rate of 2BV / h, and the eluate was collected and concentrated under reduced pressure to a constant weight to obtain the effective component.

[0049] Figure 2Results of QR activity induction experiment and NO generation inhibition experiment of multiple fractions of macroporous resin. Hepa 1c1c7 cells were inoculated in a 96-well plate and incubated in a 37°C incubator overnight. When the cell density reached about 75%, different concentrations of the test compound were added and incubated for 24 hours. The culture medium was aspirated, 30 μL of cell lysis buffer (2mM EDTA solution and 0.8% digitonin) was added, and then incubated in an incubator for 15 minutes. Then 170 μL of complete reaction mixture (bovine serum albumin, 7.5mM FAD, 150mM glucose-6-phosphate, 1.5% Tween 20, 50mM menadione, MTT, 0.5M Tris-HCl, glucose-6-phosphate dehydrogenase and 50mM NAPDH) was added. After standing at room temperature for 4 minutes, the absorbance of the solution was measured at a wavelength of 630nm using an ELISA reader. * indicates that there is a significant difference between the treatment group and the blank group (p<0.05).

[0050] RAW 264.7 mouse macrophages were inoculated in 96-well plate A. After the cells adhered to the wall, different concentrations of the test compound and LPS (1 μg / mL) culture medium were added and incubated in an incubator for 24 hours. 100 μL of supernatant was added to 96-well plate B, and then 100 μL of Griess reagent (0.1% naphthylethylenediamine, 5% phosphoric acid, 1% sulfonamide) was added and incubated for 15 minutes. The absorbance of the solution was measured at a wavelength of 570 nm using an ELISA reader. The cell survival rate in 96-well plate A was detected using the MTT assay. In this experiment, Didox (100 μM) was used as a positive control drug, and the nitrite concentration was calculated using the NaNO2 standard curve. The method for establishing the NaNO2 standard curve is as follows: prepare 0, 3.125, 6.25, 12.5, 25, and 50 μM NaNO2 (100 μL) standard solutions and add them to a 96-well plate, then add Griess reagent. * indicates that there is a significant difference between the treatment group and the model group (p<0.05).

[0051] Example 2 Qualitative analysis of effective components

[0052] Table 1 LC-MS analysis results and component identification

[0053]

[0054] The effective components here are obtained according to the preparation process in the above Example 1, and the effective components are then qualitatively analyzed:

[0055] BEH Shield RP18 chromatographic column (2.1×100 mm, 1.7 μm, Waters).

[0056] Mobile phase: acetonitrile (A)-water (B), elution conditions: 0-2 min, 2-15% A; 2-20 min, 15-55% A; 20-45 min, 55-100% A.

[0057] Results: Figure 3 , Fig. 9 , Fig.10 As shown in Table 1, there are 14 main peaks that were successfully identified, most of which are phthalide compounds, and there are also a small amount of phenolic acid compounds; two new compounds were also identified in the minor peaks and miscellaneous peaks: 1"-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxyphthalide, the structures of which are shown below: 1"-ethoxy-wallichilide has a QR induction activity equivalent to that of the positive control drug at a concentration of 50 μM, which is 2 times higher than that of the blank group, and the maximum inhibition rate of NO is 67.8%; 3-butylidene-6-hydroxy-7-ethoxyphthalide has a concentration of about 100 μM, which is equivalent to that of the QR positive control drug, which is 1.5 times higher than that of the blank group, and the maximum inhibition rate of NO is 52.7%.

[0058]

[0059] Table 21"-ethoxy-wallichilide 1 H(600MHz) and 13 C(150MHz) data(CDCl3)

[0060]

[0061]

[0062] Table 3

[0063] 3-butylidene-6-hydroxy-7-ethoxy-phthalide 1 H(600MHz) and 13 C(150MHz) data(CDCl3)

[0064]

[0065]

[0066] Example 3 Establishment and drug administration of diabetic nephropathy mouse model

[0067] C57BL / 6 strain male mice (six weeks old, 17-19 g) were purchased from Vital River. Mice were fed with sterilized feed and boiled purified water and were free to eat. The feeding room had a 12-hour light / dark cycle and a room temperature of 22±20°C. After one week of adaptive feeding, the mice received intraperitoneal injection (ip) of sodium citrate solution (pH 4.5 control group) or 50 mg / kg streptozotocin (STZ dissolved in sodium citrate, pH 4.5) for 5 consecutive days to induce a diabetic model. After two weeks, mice with a 6-hour fasting blood glucose level (6-hour fasting) higher than 11.9 mmol / L were used for subsequent experiments. All animal experiments were carried out with the approval of the Ethics Committee and the Institutional Animal Care and Use Committee of Shandong University. The same batch of C57BL / 6 male mice were divided into six groups, namely blank control group, streptozotocin group (model group), clinical anti-DN drug captopril positive control group (positive drug group 100 mg / kg), effective component low-dose group (10 mg / kg), effective component high-dose group (20 mg / kg) and Chuanxiong ethanol extract group (20 mg / kg). Except for the blank control group, the other five groups used the above-mentioned successful modeling mice. During the entire breeding process, the drug was administered daily (the blank control and STZ groups were given normal saline). The mental state, activity, hair and limbs of the mice were observed every day. Body weight, blood sugar, diet, water intake and urine volume were measured once a week, and the 24-hour urine of the mice was collected using a mouse metabolic cage for further analysis. The results are as follows Figure 4 As shown, the effective components increased the body weight and reduced the blood sugar of DN mice.

[0068] Example 4 Collection of mouse blood and urine and removal and testing of kidneys and brain

[0069] Mice were killed by cervical dislocation, and two kidneys were collected and weighed to detect the degree of renal hypertrophy in DN mice. Later HE staining also showed that it reduced glomerular hypertrophy. After weighing both kidneys, one was placed in 4% paraformaldehyde to make paraffin sections, and the other was made into 10% tissue homogenate with normal saline. Rat brain tissue was extracted, rinsed with 0.9% sodium chloride solution, and foreign matter adhering to its surface was cleaned. The surface moisture was absorbed with clean gauze and placed in a clean centrifuge tube, which was stored at -80°C for testing biomarkers.

[0070] Example 5 Hematoxylin and eosin (HE) / PAS staining of mouse kidney

[0071] Mouse kidney tissue was taken, fixed in formalin solution, washed, alcohol dehydrated, paraffin embedded and sliced; tissue sections were dewaxed, washed, hematoxylin stained / PAS stained, washed, eosin stained, sealed according to the HE staining process, observed under a microscope and photographed. Figure 5 and Figure 6As shown, the active ingredients can reduce the aggregation of inflammatory cells, alleviate glomerular hypertrophy, and improve the level of renal fibrosis.

[0072] Example 6 Effects of the active ingredients on Nrf2 and downstream gene proteins, fibrosis-related proteins TGF-β1, α-SMA

[0073] Methods: Western blot analysis was used to detect changes in protein levels in mouse kidneys.

[0074] Take the kidney tissue sample out of the -80℃ freezer, weigh an appropriate amount of sample into a 1.5mL EP tube, and cut it into pieces with scissors. Add sample buffer according to the proportion, grind the tissue sample with an electric grinder until there are no obvious tissue clumps, place it on ice for 30 minutes, centrifuge it using a centrifuge (10000rpm, 15min, 4℃), take the supernatant and heat it on a 100℃ metal heater for 5 minutes, and ultrasonically crush it for 36 seconds to obtain the sample. After the processed kidney tissue sample is analyzed by SDS gel electrophoresis, it is transferred to the membrane, blocked, and the corresponding antibody is added. It is incubated at 4℃ overnight, washed with PBST, and incubated with horseradish peroxidase-coupled secondary antibody for 1h. Protein analysis is performed by enhanced ECL chemiluminescence. The results are as follows: Figure 7 As shown in the results, the effective components can upregulate the expression of Nrf2 and its downstream gene proteins and reduce the levels of fibrosis-related proteins TGF-β1 and α-SMA.

[0075] Example 7 Effect of active ingredients on NF-κB signaling pathway

[0076] HK-2 cells were inoculated in a 35 mm diameter culture dish and cultured until the density reached 70% to 80%. Different concentrations of the active components were added and treated with a medium containing LPS (1 μg / mL) for 24 hours. The cells were washed twice with PBS and the cell lysis solution was added to collect the protein. The corresponding protein was then detected using the above-mentioned immunoblotting method. The results are shown in Figure 8 As shown, the activation of NF-κB signaling pathway induced by LPS can be effectively reduced after cells are treated with effective components.

[0077] Example 8 Effect of the active ingredients on oxidative stress levels in brain tissue of DN mice

[0078] Diabetic nephropathy is a complication induced by diabetic microangiopathy. The microvessels in the brain are concentrated, dense and complex, so diabetes also causes serious damage to brain tissue, which is mainly manifested in the increase of oxidative stress and inflammatory factors. When the brain tissue is insufficiently oxygenated, a large number of oxygen free radicals will be produced, leading to excessive consumption of SOD and CAT reductase. Excess oxygen free radicals will promote the generation of cytotoxic MDA. Through ELISA detection of DN mouse brain tissue, it was found that the effective components improved the levels of SOD, CAT and MDA in the model rats, thereby inhibiting oxidative stress damage in rat brain tissue, increasing the activity of SOD and CAT in the brain tissue of DN mice, and reducing the production of lipid peroxide MDA. Through this antioxidant effect, it plays a neuroprotective role and reduces nerve cell apoptosis.

[0079] Example 9 Preparation of Tablets

[0080] 30 g of the effective component (prepared in Example 1) is added with 40 g of corn starch and 20 g of dextrin, and the mixture is thoroughly mixed to prepare granules. The granules are dried and granulated, and an appropriate amount of talcum powder is added and tablets are obtained.

[0081] Example 10 Preparation of capsules

[0082] 30 g of the effective component (prepared in Example 1) is added with 30 g of starch, 15 g of dextrin and 10 g of microcrystalline cellulose, and the mixture is thoroughly mixed to prepare granules. The granules are dried and granulated, and an appropriate amount of magnesium stearate is added to the granules. The granules are then filled into capsules to obtain the product.

[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing a Ligusticum chuanxiong extract for treating diabetic nephropathy, characterized in that: The steps include: Using 65%-95% ethanol solution as extraction solvent, soaking Chuanxiong at 20-30°C for 3-5h, and then reflux extraction at 50-100°C for 2-4h to obtain an extract; The extract is refined, concentrated and dried to obtain the ethanol extract of Chuanxiong; Using a macroporous adsorption resin column to separate and purify the ethanol extract of Chuanxiong, and collecting the eluents of each part; The eluates of each part are concentrated and dried to obtain extracts of each part; The QR induction activity test and NO generation inhibition test were used to screen the extracts from each part to obtain the target component; The mass of the extraction solvent is 8-12 times the mass of Chuanxiong; The extraction temperature is 70-90°C; The macroporous adsorption resin column is HPD-100, HPD-400 or D101; When using a macroporous adsorption resin column for separation, the eluent is 67.5% ethanol by volume, the elution volume is 3-5 BV, and the elution flow rate is 1.5-2.5 BV / h; The obtained extract includes 1''-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxy-phthalide, wherein the structural formulas of 1''-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxy-phthalide are shown as follows: 。 2. The method for preparing the Chuanxiong extract for treating diabetic nephropathy according to claim 1, characterized in that: The refining method is an activated carbon adsorption clarification method or a reduced pressure filtration method.

3. The method for preparing the Chuanxiong extract for treating diabetic nephropathy according to claim 1, characterized in that: The concentration is reduced pressure concentration, and the drying is vacuum drying or freeze drying.

4. A Ligusticum chuanxiong extract for treating diabetic nephropathy, characterized in that: The extract is prepared by the preparation method of any one of claims 1 to 3, comprising 1''-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxyphthalide, wherein the structural formulas of 1''-ethoxy-wallichilide and 3-butylidene-6-hydroxy-7-ethoxyphthalide are as follows: 。 5. The Chuanxiong extract for treating diabetic nephropathy according to claim 4, characterized in that: The active ingredients of the Chuanxiong extract include ligusticumolide C, ligusticum lactone A, 6S,7S-3-butyl-3,6,7-trihydroxy-4,5,6,7-tetrahydrobenzamide, ligusticum lactone L3, ligusticum lactone M, thioligusticum lactone A, ligusticum lactone E, ligusticum lactone L2, ligusticum lactone C, (-)-all0aromadendrane-4β,10α,13,15-tetrol, ligusticum lactone A, Z-ligusticum lactone, oriental angelica lactone B and angelica lactone A.

6. A diabetic nephropathy drug, characterized in that: The active ingredient comprises the Chuanxiong extract according to claim 4 or 5.